Keywords
Eligibility Determination ×
Prostatic Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

393 Search results.

Eligibility Low Risk Prostate Cancer NCT01877070

- 7/6/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies; ODM derived from: https://clinicaltrials.gov/show/NCT01877070

Eligibility Low Grade Prostate Cancer NCT01192438

- 7/6/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Laser Based Focal Ablation of Low Grade Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01192438

Eligibility Localized Prostate Cancer NCT01931046

- 7/2/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01931046

Eligibility Localized Prostate Cancer NCT01902680

- 7/1/20 - 1 form, 2 itemgroups, 29 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.; ODM derived from: https://clinicaltrials.gov/show/NCT01902680

Eligibility High-risk Prostate Cancer NCT01488968

- 6/6/20 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Inclusion Criteria
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01488968

Eligibility Hormone-refractory Prostate Cancer NCT01422850

- 5/20/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT01422850

Eligibility Hormone Refractory Prostate Cancer NCT02208583

- 5/19/20 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Molecular Phenotype Changes and Personalized Treatment for CRPC; ODM derived from: https://clinicaltrials.gov/show/NCT02208583

Eligibility Prostate Cancer NCT02375035

- 4/19/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02375035

Eligibility Prostate Cancer Based on a Rise of the PSA > 4 ng / mL. NCT02050542

- 2/11/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Current Practice Which Compare the Rate of Prostate Cancer by Using 2 Kind of Transrectal Biopsies: 3 by IRM-echography Image Fusion and 12 Systematized Guided Echographies.; ODM derived from: https://clinicaltrials.gov/show/NCT02050542

Eligibility Carcinoma of the Prostate NCT01890096

- 10/13/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01890096

Eligibility Stage, Prostate Cancer NCT02403505

- 7/11/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms; ODM derived from: https://clinicaltrials.gov/show/NCT02403505

Eligibility Prostatic Neoplasms NCT02257736

- 6/25/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC); ODM derived from: https://clinicaltrials.gov/show/NCT02257736